Current Status of Pharmacovigilance Research Based on Administrative Claims Database

Abstract

Abstract: ：With the continuous improvement of the administrative claims database, more and more researchers are using the data for drug safety research. Several main administrative claims database and applications based on these database, especially pharmacovigilance research, were introduced. Additionally, two relevant regulations for the use of administrative claims data for pharmacovigilance research are also briefly introduced. We expect that the above will do some help on the pharmacovigilance research based on the insurance database of China.

Key words: administrative claims database, pharmacovigilance, adverse drug reaction, regulation

CLC Number:

R994.11

SHEN Zhuojie, XU Jinfang, YE Xiaofei, JIA Zheyu, LIANG Jizhou, WANG Meng, GUO Xiaojing. Current Status of Pharmacovigilance Research Based on Administrative Claims Database[J]. Chinese Journal of Pharmacovigilance, 2019, 16(3): 129-133.

References

[1] Uppsala Monitoring Centre.Glossary of terms used in pharmacovigilance[M]. Sweden. 2011
[2] 王大猷. 关于若干药物安全术语的定义及译法的讨论[J]. 药学服务与研究, 2014, 14(2): 81-84.
[3] 田峰, 廖星, 谢雁鸣. 欧盟《药物流行病学研究方法学标准指导手册》译介[J]. 中国中药杂志, 2013, 38(18):2949-2957.
[4] FDA. Best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data[EB/OL]. (2013-05-01) [2018-09-20]. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm243537.pdf.
[5] 朱田田, 叶小飞, 郭晓晶, 等. 基于电子医疗数据库的药物流行病学安全性研究的特点及要求[J]. 中国药物警戒, 2014, 11(7): 413-415.
[6] The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on methodological standards in pharmacoepidemiology (rev.7)[EB/OL] (EMA/95098/2010) [2018-09-20]. http://www.encepp.eu/standards_and_guidances/ documents/ENCePPGuideonMethStandardsinPE_Rev7.pdf
[7] Hall G C, Sauer B, Bourke A, et al.Guidelines for good database selection and use in pharmacoepidemiology research[J]. Pharmaco-epidemiol Drug Saf, 2012, 21(1): 1-10.
[8] 吴娅利. “新医改”对重庆市军队大型综合性医院经费补偿机制的影响及对策研究[D]. 重庆, 2013.
[9] 林瑾文, 郑孝勇. 医疗保险信息数据库应用研究[J]. 中国医药科学, 2011, 1(6): 135-136,139.
[10] 郭剑非, 雷静, 岳晓萌, 等. 如何利用观察性医药数据库进行药物流行病学的安全风险管理研究[J]. 药物流行病学杂志, 2015, 24(2):83-93.
[11] 张涛. 美国医疗保障运行机制及其对中国医疗体制改革的借鉴研究[D]. 北京, 2013.
[12] Centers for medicare & medicaid services(CMS). Fast Facts[EB/OL].(2018-08-01) [2018-09-20] https://www.cms.gov/fastfacts/.
[13] Jupiter D C, Fang X, Adhikari D, et al.Safety of continued clopidogrel use in the preoperative course of gastrointestinal surgery: A retrospective cohort study[J]. Ann Surg, 2017, 265(2): 370-378.
[14] Vangala C, Lenihan C R, Montez-Rath M E, et al. Statin use and hip fractures in U.S. Kidney transplant recipients[J]. BMC Nephrol, 2017, 18(1): 145.
[15] 天津社保经办服务标准化建设培训团组. 法国社会保障制度改革及给我们的启示[J]. 天津社会保险, 2015, (1):58-60.
[16] 人力资源和社会保障部国际合作司. 法国医疗保险制度概况[J]. 中国劳动保障, 2009, (5):61-62.
[17] 荆涛, 朱庆祥, 赵洁, 等. 论社会医疗保险和商业健康保险的有效衔接—以荷兰、法国、爱尔兰、澳大利亚的做法为例[J]. 中国医疗保险, 2012, (4):64-67.
[18] Palmaro A, Moulis G, Despas F, et al.Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies[J]. Fundam Clin Pharmacol, 2016, 30(6): 616-624.
[19] Moulis G, Lapeyre-Mestre M, Palmaro A, et al.French health insurance databases: What interest for medical research?[J]. Rev Med Interne, 2015, 36(6): 411-417.
[20] Bezin J.The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology[J]. Pharmacoepidemiol Drug Saf, 2017, 26(8): 954-962.
[21] 刘宏霞, 梁华. 甘精胰岛素和癌症的风险:一项基于法国国家医疗保险数据库的队列研究[J]. 中华糖尿病杂志, 2012, 4(8):511-512.
[22] Blin P, Lassalle R, Dureau-Pournin C, et al.Insulin glargine and risk of cancer: A cohort study in the French national healthcare insurance database[J]. Diabetologia, 2012, 55(3): 644-653.
[23] Lugardon S, Roussel H, Sciortino V, et al.Triptan use and risk of cardiovascular events: A nested-case-control study from the French health system database[J]. Eur J Clin Pharmacol, 2007, 63(8): 801-807.
[24] Neumann A, Weill A, Ricordeau P, et al.Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study[J]. Diabetologia, 2012, 55(7): 1953-1962.
[25] 孙菊. 全民覆盖视角下的韩国医疗保险制度研究[J]. 武汉大学学报:哲学社会科学版, 2013, 66(6): 83-89.
[26] Noh Y, Lee J, Shin S, et al.Antiplatelet therapy of cilostazol or sarpogrelate with aspirin and clopidogrel after percutaneous coronary intervention: A retrospective cohort study using the Korean national health insurance claim database[J]. PLoS One, 2016, 11(3): e0150475.
[27] Cheng C L, Kao Y H, Lin S J, et al.Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan[J]. Pharmacoepidemiol Drug Saf, 2011, 20(3): 236-242.
[28] Wu T Y, Majeed A, Kuo K N.An overview of the healthcare system in Taiwan[J]. London J Prim Care (Abingdon), 2010, 3(2): 115-119.
[29] Taiwan. National Health Insurance Research Database (NHIRD) [EB/OL]. (2018-09-18) [2018-09-20] http://www.nhri.org.tw/nhird/.
[30] Hsiao F Y, Hsieh P H, Huang W F, et al.Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: A nested case-control study[J]. Drug Saf, 2013, 36(8): 643-649.
[31] Lanes S F, De Luise C.Bias due to false-positive diagnoses in an automated health insurance claims database[J]. Drug Saf, 2006, 29(11): 1069-1075.
[32] 侯永芳, 沈璐, 刘巍, 等. 美国医疗产品安全主动监测系统概述及启示[J]. 中国药物警戒, 2017, 14(1):32-35.
[33] 杨羽, 詹思延. 上市后大数据药品安全主动监测模式研究的必要性和可行性[J]. 药物流行病学杂志, 2016, 25(7):401-404, 413.
[34] 国家统计局. 2018年国民经济和社会发展统计公报[EB/OL]. (2019-02-28)[2019-03-19]. http://www.stats.gov.cn/tjsj/zxfb/201902/t20190228_1651265.html.
[35] 甘枥元. 基于数据挖掘医保系统的研究[J]. 信息安全与技术, 2013, 4(10):67-69.
[36] 徐菲, 刘国恩. 医保数据应用的可及性分析[J]. 中国医疗保险, 2015, (7):51-53.
[37] 国家医保局. 统一业务标准是统一医保信息系统的先决条件[EB/OL].(2018-09-13) [2018-09-20]. https://www.zgylbx.com/index.php?m=content&c=index&a=show&catid=7&id= 33987.
[38] 陆春吉, 任慧玲, 李亚子. 大数据环境下医保数据应用探究[J]. 中国数字医学, 2016, 11(8):16-18.
[39] 杜念宇, 徐程, 舒艳, 等. 基本药物制度实施对药品价格和医疗费用的影响基于医保报销数据的实证研究[J].中国经济问题, 2015, (1):88-99.
[40] 张慧, 张超, 刘国恩, 等. 多发性骨髓瘤住院患者的直接医疗费用及其影响因素基于广州医保数据的分析[J].中国卫生政策研究, 2016, 9(11):45-51.
[41] 郭浩. 医疗保险数据分析和应用研究[D]. 合肥, 2016.
[42] 方任飞, 李静湖, 张杰, 等. 基于处方序列对称分析的他汀类药物肝脏安全性研究[J]. 中华流行病学杂志, 2016, 37(7) :935-939.
[43] 中国医疗保险. 如何推动医保大数据?告诉你其中的5个关键点[EB/OL]. (2018-06-25) [2018-09-20]. http://www.sohu.com/a/237719236_439958.
[44] 蔡婷, 闫磊, 刘述森, 等. 我国药品上市后重点监测相关问题的探讨[J]. 药物流行病学杂志, 2017, 26(5):297-301, 324.
[45] Bazelier M T, Eriksson I, De Vries F, et al.Data management and data analysis techniques in pharmacoepidemiological studies using a pre-planned multi-database approach: A systematic literature review[J]. Pharmacoepidemiol Drug Saf, 2015, 24(9): 897-905.
[46] 赵厚宇, 詹思延. 疾病风险评分在药物流行病学研究中的应用[J]. 中华流行病学杂志, 2017, 38(2): 261-266.
[47] Karp I.Adjustment strategies in studies of therapy[J]. JAMA, 2017, 317(21): 2238-2239.
[48] Armstrong K.Methods in comparative effectiveness research[J]. J Clin Oncol, 2012, 30(34): 4208-4214.
[49] Uddin M J, Groenwold R H, Ali M S, et al.Methods to control for unmeasured confounding in pharmacoepidemiology: An overview[J]. Int J Clin Pharm, 2016, 38(3): 714-723.